Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones?  by High, Stephen et al.
Minireview
Glycoprotein folding in the endoplasmic reticulum:
a tale of three chaperones?
Stephen High*, Fabienne J.L. Lecomte, Sarah J. Russell, Benjamin M. Abell, Jason D. Oliver
School of Biological Sciences, University of Manchester, 2.205 Stopford Building, Oxford Road, Manchester M13 9PT, UK
Received 5 May 2000
Edited by Gunnar von Heijne
Abstract The endoplasmic reticulum (ER) is a major site of
protein synthesis and its inside, or lumen, is a major site of
protein folding. The lumen of the ER contains many folding
factors and molecular chaperones, which facilitate protein
folding by increasing both the rate and the efficiency of this
process. Amongst the many ER folding factors, there are three
components that specifically modulate the folding glycoproteins
bearing N-linked carbohydrate side chains. These components
are calnexin, calreticulin and ERp57, and this review focuses on
the molecular basis for their capacity to influence glycoprotein
folding. ß 2000 Federation of European Biochemical Socie-
ties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
In eukaryotic cells, the endoplasmic reticulum (ER) acts as
the entry point for newly synthesised proteins to enter the
well-de¢ned secretory pathway. Hence, the ER is a major
site of protein synthesis with many nascent polypeptides being
co-translationally translocated into and across its membrane.
These polypeptides pass through the translocation sites of the
ER membrane as partially unfolded polypeptide chains. It
should therefore be no surprise that the inside, or lumen, of
the ER functions as a specialised folding environment and
that it contains a number of molecular chaperones and folding
factors [1]. This ensures that as newly synthesised polypeptides
enter the ER lumen, the nascent chains begin to fold rapidly
into their native structures.
From amongst a complex palette of ER chaperones and
folding factors, three components have been experimentally
de¢ned as interacting speci¢cally with newly synthesised gly-
coproteins, that is proteins that have been covalently modi¢ed
by the attachment of N-linked oligosaccharides. This speci¢c-
ity for glycoproteins is particularly apparent, since none of the
other known ER folding factors select their substrates purely
on the basis of whether or not they are N-glycosylated. This
article will focus speci¢cally upon these three glycoprotein-
speci¢c ER components, drawing particularly upon the more
recent developments in this area.
2. Glycoproteins are special
Historically, calnexin was the ¢rst glycoprotein-speci¢c ER
component to be identi¢ed [2]. Calnexin is an integral mem-
brane protein, and it soon transpired that its soluble homo-
logue, the resident ER luminal protein calreticulin, also inter-
acted speci¢cally with newly synthesised glycoproteins [3].
Calnexin and calreticulin share regions of high amino acid
sequence identity and have similar glycoprotein binding activ-
ities. These two ER components were initially described as
molecular chaperones on the basis that they both associated
transiently with many di¡erent newly synthesised glycopro-
teins as they entered the secretory pathway at the ER [2^4].
However, it was later shown that a principal factor in the
binding of calnexin and calreticulin to newly synthesised gly-
coproteins is the structure of the carbohydrate side chain [5,6].
In contrast to what one would expect of a classical chaperone,
the conformation of the polypeptide to which the carbohy-
drate is attached appeared to have little or no in£uence upon
the binding of calnexin and calreticulin [5^7]. In practice this
means that calnexin and calreticulin can either be described as
ER lectins that recognise a very speci¢c carbohydrate struc-
ture, or that one has to broaden one’s de¢nition of a molec-
ular chaperone [4,8,9].
3. Carbohydrate processing is important
The carbohydrate speci¢city of calnexin and calreticulin has
been well de¢ned, and both components recognise proteins
carrying one or more monoglucosylated oligosaccharide side
chains [5,6]. The monoglucosylated carbohydrate structure,
GlcNAc2Man7ÿ9Glc1, is initially generated by the action of
glucosidases I and II on the N-linked glycan precursor,
GlcNAc2Man9Glc3 [8]. The abundance of monoglucosylated
oligosaccharide present on a glycoprotein precursor will be
determined by two ER-resident enzymes. Glucosidase II re-
moves the ¢nal glucose residue generating a deglucosylated
side chain and hence removing monoglucosylated glycopro-
tein substrates, whilst UDP glucose:glycoprotein glucosyl
transferase (UGGT) can add a single glucose residue back
onto this structure, thus regenerating the monoglucosylated
side chain [10]. UGGT recognises only incompletely folded
glycoproteins as its substrate and so it is UGGT that acts
as a ‘folding sensor’ within the glycoprotein folding cycle
(see Fig. 1). Hence, UGGT detects non-native glycoproteins
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and reglucosylates them, thereby allowing further rounds of
binding to calnexin/calreticulin [8,9].
4. ERp57 ^ the missing link?
The crucial question to pose at this point is whether calnex-
in and calreticulin can actually exert any direct in£uence over
glycoprotein folding? This is a very moot point [8,9,11] and
one that we will return to later. What is now well established
is that there is a third ER component, ERp57, which plays a
key role in glycoprotein folding [12]. We believe that it is the
combination of ERp57 with both calnexin and calreticulin
(see Fig. 1) that forms the lynchpin of chaperone-mediated
glycoprotein folding in the ER and will explore this hypoth-
esis further below.
ERp57 has a host of pseudonyms and a ‘chequered’ past
[13,14]. What is very clear is that ERp57 is a member of the
protein disulphide isomerase (PDI) family [15]. Like archety-
pal PDI, ERp57 contains two ‘thioredoxin motifs’ which con-
stitute the thiol/disulphide oxidoreductase active sites of PDI
[16]. On the basis of its sequence similarity to PDI (29% iden-
tity, 56% similarity [22]), ERp57 was analysed for its func-
tional homology several years ago. It was established that
ERp57 does exhibit a thiol-dependent reductase activity, al-
beit that it was signi¢cantly less e¡ective than PDI [17^19].
These data did show that ERp57 could, at least in principle,
in£uence protein folding.
We ¢rst came across ERp57 when we were using a cross-
linking approach to analyse the interactions of newly synthe-
sised secretory and membrane proteins with ER components.
Our crucial discovery was the ¢nding that ERp57 interacts
speci¢cally with N-glycosylated polypeptides [12,13,20,21]. It
was also clearly signi¢cant that both the binding of ERp57 to
newly synthesised glycoproteins, and its subsequent release,
required the trimming of glucose residues from the N-linked
glycan [12,13,20,21]. Such a requirement for the glucose trim-
ming of N-linked glycans had previously been identi¢ed as a
hallmark for the binding of calnexin and calreticulin. Since
there was no evidence that ERp57 had any intrinsic lectin-like
properties, a prediction that was subsequently validated ex-
perimentally [27], we proposed that ERp57 functioned in con-
cert with calnexin and calreticulin to speci¢cally modulate
glycoprotein folding [12].
The most obvious molecular basis for this concerted action
was that ERp57 functioned as a speci¢c subunit of discrete
complexes formed with calnexin and calreticulin, and we
therefore set out to test this hypothesis directly. Using a vari-
ety of approaches we showed that ERp57 forms distinct com-
plexes with both calnexin and calreticulin, both within the
lumen of the ER and when the proteins are mixed in solution
[14]. We also clearly established that the binding of ERp57 to
calnexin and calreticulin is direct and does not require the
presence of the complex’s substrate (i.e. glucose-trimmed gly-
coprotein, cf. Fig. 1). The association of ERp57 with calnexin
and calreticulin is clearly speci¢c. Hence, despite its sequence
similarity, PDI does not associate with calnexin or calreticulin
in any of our assays [14], although calreticulin/PDI complexes
can be observed when the puri¢ed proteins are studied in vitro
[23].
5. The role of ERp57 in glycoprotein folding
Our current model for the role of ERp57 is that it functions
in the ER lumen as a subunit of discrete complexes formed
Fig. 1. Glycoprotein folding in the ER lumen. The N-linked oligosaccharide side chains present on newly synthesised glycoproteins are rapidly
trimmed by glucosidases I and II to generate monoglucosylated forms of the oligosaccharides (step 1). These monoglucosylated glycoproteins
are speci¢cally bound by two resident ER lectins, calnexin, an integral membrane protein, and calreticulin, its soluble homologue. By virtue of
its stable association with calnexin and calreticulin, ERp57 is brought into contact with the newly made glycoproteins (step 2) and is able to
modulate their folding. In this model we have shown the role of ERp57 as that of promoting native disulphide bond formation and this is sup-
ported by experimental evidence [27,28]. However, ERp57 may also play a more general role as a chaperone or folding factor (see text). The
glycoprotein substrate is released from calnexin or calreticulin, and thereby its speci¢c association with ERp57, after the removal of the last
glucose residue from the glycan by glucosidase II. If its folding has been successful, the native glycoprotein is free to be transported along the
secretory pathway (step 3). If the glycoprotein is incorrectly or incompletely folded the folding sensor UGGT adds back a single glucose residue
and the glycoprotein can undergo another round of lectin binding and ERp57 action (re-entry at step 2).
FEBS 23790 22-6-00
S. High et al./FEBS Letters 476 (2000) 38^41 39
with calreticulin and calnexin. We propose that it is these
complexes which directly modulate glycoprotein folding and
are therefore acting as molecular chaperones (Fig. 1). Whilst
our own work has not directly addressed the role of ERp57
during glycoprotein folding, several other recent studies do
indeed indicate that ERp57 functions to in£uence protein
folding, and con¢rm that it does so in combination with cal-
nexin and calreticulin. Firstly, several groups have demon-
strated the presence of ERp57, in addition to calnexin and
calreticulin, during the assembly of the MHC class I complex
[24^26]. The heavy chain of the MHC class I complex is a
glycoprotein, and its assembly with L2-microglobulin in the
ER appears to be mediated by a speci¢c set of ER folding
factors which includes calnexin, calreticulin and ERp57. Sec-
ondly, the PDI activity of ERp57 has been studied directly by
analysing the refolding of an authentic monoglucosylated pre-
cursor. It was found that the disulphide isomerase activity of
ERp57 is greatly enhanced by the presence of calreticulin or
calnexin [27]. This result provides direct evidence that it is the
combination of ERp57 with calnexin or calreticulin that spe-
ci¢cally modulates glycoprotein folding, in this case by pro-
moting the formation of native disulphide bonds [27]. Thirdly,
a direct role for ERp57 in the speci¢c catalysis of native
disulphide bond formation in glycoproteins has recently
been experimentally demonstrated [28]. Hence, mixed disul-
phide species formed in vivo between ERp57 and speci¢c viral
glycoprotein substrates could be identi¢ed [28]. These mixed
disulphides represent transient intermediates during the catal-
ysis of disulphide bond formation and exchange [29], and they
were only obtained with ERp57 when the precursors were
both N-glycosylated and suitably glucose-trimmed [28].
The precise molecular basis for the dramatic increase in
disulphide isomerase activity that is observed by combining
ERp57 with calnexin or calreticulin remains to be established.
The ER lectins calnexin and calreticulin may simply act to
bring a chaperone (ERp57) and its substrate (a glucose-
trimmed glycoprotein) together e⁄ciently [27]. This role could
be more re¢ned, since the relative positions of the glycans and
cysteine residues within a polypeptide might speci¢cally facil-
itate the formation of particular disulphide bonds. In contrast
to the stimulation of ERp57 activity, the binding of glycopro-
tein substrates to calnexin or calreticulin inhibits the isomer-
ase activity of PDI in vitro [27]. Whether this inhibition of
PDI function is in any way a crucial facet of the glycoprotein
speci¢c folding pathway of the ER lumen is also at present
unclear.
6. Where to next?
It seems clear that ERp57 functions as a glycoprotein-spe-
ci¢c PDI, but does ERp57 have any other functions? It is
surely signi¢cant that ERp57 can associate with glycoproteins
that lack any cysteine residues, and that do not therefore
require any intramolecular disulphide exchange [12,13]. This
observation suggests that the actions of ERp57 may not be
limited to the catalysis of disulphide bond formation and ex-
change. Rather, as appears to be the case for PDI, ERp57
may have a wider role as a molecular chaperone [15]. Follow-
ing the identi¢cation of a role for calnexin and calreticulin in
glycoprotein folding, a recurring question has been what do
these ER lectins actually do, and can they exert any direct
in£uence over protein folding. Whilst our own analysis of
glycoprotein folding has highlighted the contribution of
ERp57, others have now shown that both calnexin and calre-
ticulin can in£uence the in vitro refolding of proteins in the
absence of ERp57 [30,31]. In these assays, an e¡ect on both
glycosylated and non-glycosylated proteins was observed, and
calnexin and calreticulin both behaved as classical molecular
chaperones [30,31].
Since the initial identi¢cation of calnexin as a glycoprotein-
speci¢c ER component [2] we have come a long way in our
understanding of how newly synthesised glycoproteins are
folded in the ER lumen. A combination of recent publications
[30^32] and our own better judgement tell us that there is still
much to understand.
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